Patient characteristics according to KIT mutation
| Characteristic . | All patients (n = 199) . | KIT unmutated (n = 136) . | KIT mutated (n = 63) . | P . |
|---|---|---|---|---|
| Chimera transcript type, n (%) | 1.00 | |||
| RUNX1-RUNX1T1 | 132 (66) | 90 (66) | 42 (67) | |
| CBFB-MYH11 | 67 (34) | 46 (34) | 21 (33) | |
| Sex, n (%) | .53 | |||
| Male | 125 (63) | 81 (61) | 42 (67) | |
| Female | 74 (37) | 55 (39) | 21 (33) | |
| Age, y | .72 | |||
| Median | 41 | 41 | 41 | |
| Range | 16-64 | 17-64 | 16-64 | |
| WBC, ×109/L | .12 | |||
| Median | 9.6 | 8.5 | 12.1 | |
| Range | 0.80-287.0 | 0.80-287.0 | 1.84-192.4 | |
| BM blasts, % | <.001 | |||
| Median | 61.2 | 53.8 | 73.5 | |
| Range | 10.8-97.0 | 10.8-96.5 | 26.1-97.0 | |
| WBC index* | .002 | |||
| Median | 4.73 | 3.35 | 6.11 | |
| Range | 0.35-41.3 | 0.35-41.3 | 0.93-29.6 | |
| Extramedullary tumor, n (%) | 20 (10) | 13 (10) | 7 (11) | .80 |
| CD19 expression, n/N (%) | 68/192 (35) | 49/129 (38) | 19/63 (30) | .34 |
| CD56 expression, n/N (%) | 91/193 (47) | 56/130 (43) | 35/63 (56) | .13 |
| Induction therapy, n (%) | .27 | |||
| Daunorubicin base | 68 (34) | 43 (32) | 25 (40) | |
| Idarubicin base | 131 (66) | 93 (68) | 38 (60) | |
| Induction cycle, n (%) | 1.00 | |||
| 1 course | 187 (94) | 128 (94) | 59 (93) | |
| 2 courses | 12 (6) | 8 (6) | 4 (6) | |
| Additional cytogenetic abnormalities (n = 197), n/N (%) | ||||
| Loss of X/Y | 78/197 (40) | 55/135 (40) | 23/62 (38) | .64 |
| Trisomy 8 | 7/197 (4) | 4/135 (3) | 3/62 (5) | .68 |
| Trisomy 22 | 18/197 (9) | 11/135 (8) | 7/62 (11) | .60 |
| del(9q) | 14/197 (7) | 12/135 (9) | 2/62 (3) | .23 |
| del(7q)/-7 | 4/197 (2) | 3/135 (2) | 1/62 (2) | 1.00 |
| Complex | 14/197 (7) | 7/135 (5) | 7/62 (11) | .14 |
| Characteristic . | All patients (n = 199) . | KIT unmutated (n = 136) . | KIT mutated (n = 63) . | P . |
|---|---|---|---|---|
| Chimera transcript type, n (%) | 1.00 | |||
| RUNX1-RUNX1T1 | 132 (66) | 90 (66) | 42 (67) | |
| CBFB-MYH11 | 67 (34) | 46 (34) | 21 (33) | |
| Sex, n (%) | .53 | |||
| Male | 125 (63) | 81 (61) | 42 (67) | |
| Female | 74 (37) | 55 (39) | 21 (33) | |
| Age, y | .72 | |||
| Median | 41 | 41 | 41 | |
| Range | 16-64 | 17-64 | 16-64 | |
| WBC, ×109/L | .12 | |||
| Median | 9.6 | 8.5 | 12.1 | |
| Range | 0.80-287.0 | 0.80-287.0 | 1.84-192.4 | |
| BM blasts, % | <.001 | |||
| Median | 61.2 | 53.8 | 73.5 | |
| Range | 10.8-97.0 | 10.8-96.5 | 26.1-97.0 | |
| WBC index* | .002 | |||
| Median | 4.73 | 3.35 | 6.11 | |
| Range | 0.35-41.3 | 0.35-41.3 | 0.93-29.6 | |
| Extramedullary tumor, n (%) | 20 (10) | 13 (10) | 7 (11) | .80 |
| CD19 expression, n/N (%) | 68/192 (35) | 49/129 (38) | 19/63 (30) | .34 |
| CD56 expression, n/N (%) | 91/193 (47) | 56/130 (43) | 35/63 (56) | .13 |
| Induction therapy, n (%) | .27 | |||
| Daunorubicin base | 68 (34) | 43 (32) | 25 (40) | |
| Idarubicin base | 131 (66) | 93 (68) | 38 (60) | |
| Induction cycle, n (%) | 1.00 | |||
| 1 course | 187 (94) | 128 (94) | 59 (93) | |
| 2 courses | 12 (6) | 8 (6) | 4 (6) | |
| Additional cytogenetic abnormalities (n = 197), n/N (%) | ||||
| Loss of X/Y | 78/197 (40) | 55/135 (40) | 23/62 (38) | .64 |
| Trisomy 8 | 7/197 (4) | 4/135 (3) | 3/62 (5) | .68 |
| Trisomy 22 | 18/197 (9) | 11/135 (8) | 7/62 (11) | .60 |
| del(9q) | 14/197 (7) | 12/135 (9) | 2/62 (3) | .23 |
| del(7q)/-7 | 4/197 (2) | 3/135 (2) | 1/62 (2) | 1.00 |
| Complex | 14/197 (7) | 7/135 (5) | 7/62 (11) | .14 |
WBC index calculated in patients with RUNX1-RUNX1T1.